We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Research Collaboration and Commercial License Agreement Sample Contracts

Standard Contracts

CONFIDENTIAL FIRST AMENDMENT TO AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT
Research Collaboration and Commercial License Agreement • June 1st, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations

This First Amendment (the “First Amendment”) to Amended and Restated Research Collaboration and Commercial License Agreement, as amended, made as of this [09] day of March, 2017 (the “First Amendment Effective Date”), is by and between

AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT between MERSANA THERAPEUTICS, INC. and MILLENNIUM PHARMACEUTICALS, INC. dated January 29, 2016
Research Collaboration and Commercial License Agreement • June 1st, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts

This AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT is entered into as of the 29th day of January, 2016 (the “Amendment Effective Date”) by and between:

SECOND AMENDMENT TO AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT
Research Collaboration and Commercial License Agreement • August 11th, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations

This Second Amendment (the “Second A&R Amendment”) to Amended and Restated Research Collaboration and Commercial License Agreement, as amended, made as of this 2nd day of August, 2017 (the “Second A&R Amendment Effective Date”), is by and between

THIRD AMENDMENT TO AMENDED AND RESTATED RESEARCH COLLABORATION AND COMMERCIAL LICENSE AGREEMENT
Research Collaboration and Commercial License Agreement • November 13th, 2017 • Mersana Therapeutics, Inc. • Pharmaceutical preparations

This Third Amendment (the “Third A&R Amendment”) to the Amended and Restated Research Collaboration and Commercial License Agreement, dated January 29, 2016, as amended from time to time (the “Original Agreement”), made as of this30th day of October, 2017 (the “Third A&R Amendment Effective Date”), is by and between